The first patient has been dosed in a phase 1 clinical trial of CT-95 among patients with mesothelin-expressing solid tumors.

Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck ...

After living with lymphoma for 15 and a half years, my doctor has suggested reducing the dose of my medication and possibly ...

Because the five-year relative survival rate for people with esophageal cancer is approximately 22%, this makes early ...

A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was ...

Dr. Sheri Yolanda Prentiss discusses lymphedema as a result of cancer treatment and shares resources that exist for patients ...

The American Heart Association has released a statement detailing cardiometabolic considerations for survivors of childhood ...

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Cancer is a distraction and not always a bad one. We do learn perspective. There are some good things we can take away in ...

Bavencio as first-line maintenance was associated with long-term efficacy in advanced urothelial carcinoma regardless of ...